Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT05929612

A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma

Led by M.D. Anderson Cancer Center · Updated on 2026-01-09

50

Participants Needed

1

Research Sites

231 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To learn if response-adapted, ultra-low dose radiation therapy can help to control MZL. This means participates first receive lower does of radiation therapy and then, based on how the disease responds, may receive higher doses after that.

CONDITIONS

Official Title

A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients 18 years or older
  • Diagnosed with stage I-II marginal zone lymphoma or low grade B cell lymphoma favoring marginal zone lymphoma
  • No planned systemic therapy before first follow-up after radiation
  • If previously treated with other modalities, must have measurable residual disease
  • Prior systemic therapy allowed if before most recent disease assessment
  • Prior antibiotics or topical therapies for lymphoma allowed if before most recent disease assessment
  • For gastric MALT lymphoma, required Helicobacter pylori testing on biopsy specimen
  • Female patients of childbearing potential must have negative pregnancy test within 1 week of radiation
  • Agreement to use adequate contraception for women of childbearing potential and men during radiation and for 4 months after
  • Ability to understand and sign informed consent
  • Patients with bulky tumors (>7.5 cm) allowed
  • Patients with prior or concurrent malignancies that do not interfere with study assessments allowed
Not Eligible

You will not qualify if you...

  • Psychiatric illness or social situations limiting study compliance
  • Pregnant women
  • Lymphoma diagnoses other than marginal zone lymphoma
  • History of radiation to the treated site exceeding safe tolerance levels
  • Active scleroderma under treatment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

MD Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

Loading map...

Research Team

J

Jillian Gunther, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma | DecenTrialz